Redirection of SARS-CoV-2 to phagocytes by intranasal sACE2-Fc as a universal decoy confers complete prophylactic protection
eLife · 2026
DOI: 10.7554/elife.108883 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Jingyi Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, Faculty of Medicine; GIBH CAS-CUHK Joint Research Laboratory on Stem Cell and Regenerative Medicine, The Chinese Unive…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, SARS-CoV-2, Phagocytes, COVID-19. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Grants Council, University Grants Committee, Innovation and Technology Commission, Chinese University of Hong Kong.
Abstract (Originalsprache)
The rapid evolution of SARS-CoV-2 and other respiratory RNA viruses limits the success of current vaccines and antibody-based therapies. Engineered decoy receptors based on soluble angiotensin-converting enzyme 2 (sACE2) offer promising alternatives but show limited clinical success. This study conducted functional and mechanistic analyses using an optimized sACE2 mutant fused to human IgG1 Fc (B5-D3) as a representative, revealing redirection of virus–decoy complexes from epithelial infection to lysosomal degradation in phagocytes beyond viral neutralization. Intranasal prophylactic delivery of B5-D3 confers complete protection in SARS-CoV-2-infected K18-hACE2 mice, regardless of age. Abrogation of Fc effector functions compromises antiviral protection, indicating that Fc-mediated uptake of virus–decoy complexes is critical. Transcriptomic analysis suggests that B5-D3 induces early immune activation in the lungs of infected mice. Bio-distribution and flow cytometry reveal selective targeting of airway phagocytes. In vitro assays confirm lysosomal degradation of virus–decoy complexes by macrophages without productive infection. These findings reveal a distinct antiviral mechanism via phagocytic clearance, supporting refined regimens for decoy treatments against SARS-CoV-2 and potentially other respiratory viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences, Faculty of Medicine; GIBH CAS-CUHK Joint Research Laboratory on Stem Cell and Regenerative Medicine, The Chinese University of Hong Kong, Hong Kong, China.
- Centre for Immunology and Infection, Hong Kong Science and Technology Park, Hong Kong, China.
- School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
- Centre for Regenerative Medicine and Health, Hong Kong Institute of Science and Innovation, Chinese Academy of Sciences, Hong Kong, China.
- Department of Cardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.
- HKU-Pasteur Research Pole, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
ORCID-Profile: Jingyi Wang, Jiangchuan Li, Alex W H Chin, Yin Xia, Thomas Braun, Leo L M Poon, Bo Feng
Förderung
- Research Grants Council, University Grants Committee
- Innovation and Technology Commission
- Chinese University of Hong Kong
Zitieren
APA
Wang, J., Li, J., Chin, A. W. H., Luo, B., Wei, J., Qiu, J., Ren, J., Xia, Y., Braun, T., Poon, L. L. M., & Feng, B. (2026). Redirection of SARS-CoV-2 to phagocytes by intranasal sACE2-Fc as a universal decoy confers complete prophylactic protection. eLife. https://doi.org/10.7554/elife.108883
Vancouver
Wang J, Li J, Chin AWH, Luo B, Wei J, Qiu J, et al. Redirection of SARS-CoV-2 to phagocytes by intranasal sACE2-Fc as a universal decoy confers complete prophylactic protection. eLife. 2026. doi:10.7554/elife.108883
BibTeX
@article{Wang2026,
author = {Wang, Jingyi and Li, Jiangchuan and Chin, Alex W H and Luo, Bin and Wei, Junkang and Qiu, Jiale and Ren, Jianwei and Xia, Yin and Braun, Thomas and Poon, Leo L M and Feng, Bo},
title = {Redirection of SARS-CoV-2 to phagocytes by intranasal sACE2-Fc as a universal decoy confers complete prophylactic protection},
journal = {eLife},
year = {2026},
doi = {10.7554/elife.108883}
}
EUVIMED